Clinical trials: psoriasis
Psoriasis, Plaque Psoriasis
Study to Evaluate Safety and Efficacy of Oral MP1032 in Psoriasis Patients
This Phase IIa study is designed to assess the safety, tolerability and pharmacokinetics of oral MP1032 in patients with moderate to severe psoriasis over a period of 6 weeks.
- Trial name
- NCT02908347
- Testing
- MP1032
- Where
- 4 sites in Germany
- Volunteers
- 46 people
- Sponsor
- MetrioPharm AG
Moderate to Severe Psoriasis
Safety, Tolerance, Efficacy and Pharmacokinetics of JS005 Multiple Dosing
JS005-002 is a randomized, double-blinded, placebo-controlled phase Ib/II clinical study to evaluate the safety, tolerability, efficacy and pharmacokinetic profiles of multiple doses of JS005 (recombinant humanized anti-IL-17A…
- Trial name
- NCT05344248
- Testing
- JS005 (recombinant humanized monoclonal antibody against IL-17A)
- Where
- 22 sites in China
- Volunteers
- 183 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Arthritis, Psoriatic
BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis
The overall purpose of this trial is to assess clinical efficacy and safety of different subcutaneous doses of BI 655066/ABBV-066/risankizumab in adult patients with psoriatic arthritis in order to select doses for further…
- Trial name
- NCT02719171
- Testing
- risankizumab
- Volunteers
- 185 people
- Sponsor
- AbbVie
Psoriasis
Effective Study of Live Attenuated Varicella Vaccine to Treat Severe Resistant Psoriasis
Immunotherapy was reported in the treatment of psoriasis. Treatment of resistant psoriasis may be difficult and cyclosporine can induce some remission.
- Trial name
- NCT01356004
- Testing
- live attenuated chicken pox vaccine, saline, efficacy
- Where
- Egypt
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Cairo University
Rheumatoid Arthritis, Psoriatic Arthritis
Study to Characterize Demographics, Compliance, Tolerability and Safety in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Prescribed Adalimumab (Humira®) as Part of Routine Clinical Care
The primary objective of this post-marketing observational study was to obtain data on the characteristics (patient age/gender; disease type, severity and duration; disease specific treatment history; current concomitant…
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis
- Trial name
- NCT01163916
- Where
- 43 sites in Russia
- Volunteers
- 252 people
- Sponsor
- Abbott
Psoriatic Arthritis
Special Investigation in Patients With Psoriatic Arthritis (PsA) (Working Productivity and Activity Impairment [WPAI])
A special investigation (post marketing observational study [PMOS]/non-mandatory) of HUMIRA® in Japanese psoriatic arthritis patients who are engaged in paid work.
- Trial name
- NCT02414633
- Volunteers
- 148 people
- Sponsor
- AbbVie
Psoriasis Vulgaris
Topical Diacerein in Psoriasis Vulgaris
The goal of this clinical trial is to evaluate the safety and effectiveness of topical diacerein in adults with psoriasis vulgaris.
- Trial name
- DIA (NCT07352306)
- Testing
- Diacerein
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Alaa Ashraf Muhammad Helal
Plaque Psoriasis, Psoriatic Arthritis
Real-World Study of Xeligekimab for Moderate to Severe Plaque Psoriasis(XP-Real)
Xeligekimab Injection was approved in China on August 20, 2024, for treating adults with moderate to severe plaque psoriasis who are candidates for systemic treatment or phototherapy.
- Conditions
- Plaque Psoriasis, Psoriatic Arthritis, Scalp Psoriasis, Nail Psoriasis
- Trial name
- NCT06802848
- Testing
- Xeligekimab injection
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Chongqing Genrix Biopharmaceutical Co., Ltd
Plaque Psoriasis
A Study to Assess S011806 (DC-806 or LY4100504) in Healthy Adult Participants and Participants With Chronic Plaque Psoriasis
The main purpose of this study is to learn more about the safety and side effects of DC-806 when given by mouth to healthy participants and participants with Chronic Plaque Psoriasis. The study will have three parts.
- Trial name
- NCT06808815
- Testing
- DC-806
- Where
- United Kingdom
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Psoriasis
A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis
This is a Phase 2, multicenter, open-label study in subjects with moderate to severe plaque psoriasis aged 6 to 17 years, inclusive, intended to assess the safety, tolerability, and PK of apremilast with 2 weeks of oral…
- Trial name
- NCT02576678
- Testing
- Apremilast
- Where
- 18 sites in United States, Canada and 2 more
- Volunteers
- 42 people
- Sponsor
- Amgen
Psoriasis
A Study to Assess the Long-Term Safety of Tacrolimus Cream in the Treatment of Psoriasis
A study to assess the long-term safety of tacrolimus cream in the treatment of psoriasis
- Trial name
- NCT00293917
- Testing
- Tacrolimus Cream
- Where
- 37 sites in United States, Canada
- Volunteers
- 658 people
- Sponsor
- Astellas Pharma Inc
Rheumatoid Arthritis, Psoriasis Arthritis
Prospective Evaluation of the Radiographic Efficacy of Enbrel
It is known from the COMET-trial that patients who start Enbrel treatment early have a great chance of reaching clinical remission and radiographic nonprogression.
- Trial name
- PRERA (NCT01623752)
- Testing
- Etanercept
- Volunteers
- 1,821 people
- Sponsor
- Pfizer
Psoriasis Vulgaris
Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight
This study investigates if an adjusted brodalumab dosage regimen will give improved efficacy in psoriasis in patients with a body weight of over 120 kg.
- Trial name
- ADJUST (NCT04306315)
- Testing
- Brodalumab
- Where
- 81 sites in Belgium, Czechia and 9 more
- Volunteers
- 385 people
- Sponsor
- LEO Pharma
Psoriasis
Ethoximod Pharmacokinetics In Healthy Subjects
The goal of this clinical trial is to evaluate the tolerability, pharmacokinetics and pharmacodynamics of Ethoximod in healthy subjects. The main questions it arms to answer are: 1.
- Trial name
- NCT06361212
- Testing
- Ethoximod
- Where
- China
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Longevity Inc.
Psoriasis, Depression
Identification of the Best Self-questionnaire to Diagnose Depression in Patients With Psoriasis (DePsoVal)
Prevalence of depression shows great heterogeneity in patients with psoriasis. This could be explained by the psychometric properties of the questionnaires assessing depressive symptoms: these tests have not been developed in a…
- Trial name
- DePsoVal (NCT04013867)
- Where
- France
- Volunteers
- 289 people
- Sponsor
- University Hospital, Clermont-Ferrand
Arthritis, Psoriatic, Psoriasis
Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by Dermatologists
The purpose of this study is to evaluate the safety profile and the effectiveness of etanercept under usual care settings in patients with PsA treated by dermatologists.
- Conditions
- Arthritis, Psoriatic, Psoriasis, Skin Diseases, Papulosquamous
- Trial name
- NCT00293709
- Testing
- etanercept
- Where
- Germany
- Volunteers
- 129 people
- Sponsor
- Pfizer
Nail Psoriasis
Clinical Study on the Medical Device PROXERA PSOMED 30 for the Treatment of Nail Psoriasis: Evaluation of Safety and Efficacy
The purpose of this interventional clinical study is to evaluate the safety and efficacy of PROXERA PSOMED 30, a topical medical device containing 30% urea, for the treatment of nail psoriasis in adults with nail psoriasis.
- Trial name
- NAPSI (NCT07546032)
- Testing
- Device intervention name: PROXERA PSOMED 30 nail cream; Control intervention name: Petrolatum
- Where
- Italy
- Volunteers
- 21 people
- Sponsor
- ICIM International S.r.l.
Psoriasis
Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis
This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study of the efficacy and safety of apremilast (CC-10004) in pediatric subjects with moderate to severe plaque psoriasis.
- Trial name
- NCT03701763
- Testing
- Apremilast (CC-10004)
- Where
- 99 sites in United States, Belgium and 8 more
- Volunteers
- 245 people
- Sponsor
- Amgen
Rheumatic Disease
Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty
The purpose of this study is to assess the incidence of rheumatologic flares, changes in pain scores (VAS), changes in functional outcomes (PROMIS), wound complications, surgical site infections, and return trips to the operating…
- Trial name
- NCT07138898
- Testing
- Methotrexate, Sulfasalazine, Hydroxychloroquine
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- NYU Langone Health
Psoriasis
A Safety/Efficacy Study of a Non-steroid, Topical Cream Treatment of Psoriasis Over 12-weeks
Psoriasis is a chronic inflammatory skin disorder that is characterized by hyperproliferation of the keratinocytes and inflammation of the epidermal and dermal layers of the skin.
- Trial name
- 134993 (NCT01098721)
- Testing
- WBI-1001
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Welichem Biotech Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.